Scientific Validation of Siddha Drug “Kadukkai Vadagam” for its Bronchodilator, Anti-Histamine and Anti-Oxidant properties in Rodents

Kalpana, A (2017) Scientific Validation of Siddha Drug “Kadukkai Vadagam” for its Bronchodilator, Anti-Histamine and Anti-Oxidant properties in Rodents. Masters thesis, Government Siddha Medical College, Chennai.


Download (14MB) | Preview


In our Siddha literature symptoms of the Swasa kasam was correlated with bronchial asthma. Generally due to the imbalance of the prana vayu, three humours in the body gets vitiated, then it leads to broncho constriction. Hence the author conducts the detailed scientific validation of Kadukkai Vadagam for Bronchodilator activity, Anti-oxidant activity and Anti-histamine activity. The study was accepted by Institutional screening committee and then approved by the Institutional Animal Ethical Committee (IAEC). In this study, various types of analyzing studies for efficacy and toxicity were conducted in the SCRI and Baid Metha College. In the Organoleptic studies KV has dark brown colour, sour in taste, hard in touch, 1cm in size and slightly soluble in water. In the Physiochemical analysis studies, KV has contains Total ash 15.12%, Water soluble ash 3.13%, Acid insoluble ash 0.68%, Water soluble extractive 44.00%, Alcohol soluble extractive 45.81%. The phytochemical analysis reveals the presence of Glycosides, Saponin, Carbohydrate, Phytosterol, Phenol, Triterpenes and Protein which act as a defence system against diseases and more accurately to protect against swasa kasam diseases. In HPTLC analysis finger print scanned at wave length 254 nm for chloroform extract of KV. There are ten polyvalent phyto constituents and corresponding ascending order of Rf values start from 0.05 to 0.89 in which highest concentrations of the phyto constituents was found to be 44.97 % and 10.88 % with its corresponding Rf value were found to be 0.22 and 0.75 respectively. In the Bio-Chemical analysis of the KV drug contains Sodium, Potassium which stimulates normal respiratory mechanism in bronchial asthma. In the examination of KV drug, bacterial and fungal load has within the WHO norms. Hence the drug KV is safe. In the FTIR instrumental analysis, the drug KV contains presence of Alcohol, Phenols, Esters, Amines, Acid, Aromatics, Alkyl halides, Alkene, Ether and alkanes which are represents the peak value. OH group has higher potential towards inhibitory activity against airway inflammation. Amines and Carboxylic acids possess which enhances the drug effect against the disease. In the SEM Analysis, KV drug contains the micro size particle of the sample. ICP-OES results indicate that the formulation is extremely safe as it contains heavy metals below detectable limits. XRD pattern of the trail drug KV shows some good crystalinity. The major diffraction peaks are identified after XRD analysis. The acute toxicity result shows no mortality rate up to 2000mg/kg. It showed changes in alertness, grooming, touch response. The behavioral changes are normal. Hence the test drug KV is a safe herbal drug and can be used for long time administration. There is no toxicological abnormality seen in the vital organs after administration of the test drug KV. Thus the safety of the drug is revealed so that it can be administered for long time without any side effects. In the Pharmacological study KV possesses bronchodilator activity, Antihistamine activity and Anti oxidants. Hence, It can reduce the sympotoms of asthma and improve pulmonary funtions. An incredible action of this drug value against the disease of Bronchial asthma has been revealed from this study of. KV. This must be implicated in the future clinical studies and preclinical chronic toxicity studies.

Item Type: Thesis (Masters)
Additional Information: (Reg no: 321412105)
Uncontrolled Keywords: Scientific Validation ; Siddha Drug ; Kadukkai Vadagam ; Bronchodilator ; Anti-Histamine ; Anti-Oxidant properties ; Rodents.
Subjects: AYUSH > Gunapadam
Depositing User: Subramani R
Date Deposited: 02 Oct 2018 13:40
Last Modified: 02 Oct 2018 13:40

Actions (login required)

View Item View Item